Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 105,108 Shares of Stock

Key Points

• Evolus insider David Moatazedi sold 105,108 shares at an average price of $9.04, generating approximately $950,176. After the sale, he retained 499,592 shares, a 17.38% reduction in his direct holdings.
• Evolus shares rose 2.8% to $9.30, near the company’s 52-week high of $9.31. The stock has a market capitalization of about $614 million, while institutional investors own 90.69% of its shares.
• Analyst sentiment remains generally positive, with an average rating of “Moderate Buy” and a consensus price target of $14.50; several firms maintain Buy ratings with $13 targets.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 105,108 shares of the company's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the transaction, the insider directly owned 499,592 shares of the company's stock, valued at $4,516,311.68. This represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Evolus Stock Up 2.8%

Shares of NASDAQ:EOLS traded up $0.25 during mid-day trading on Friday, reaching $9.30. 684,831 shares of the stock were exchanged, compared to its average volume of 1,087,866. The company has a market cap of $614.26 million, a P/E ratio of -17.88 and a beta of 1.42. Evolus, Inc. has a one year low of $3.86 and a one year high of $9.31. The stock's 50 day simple moving average is $7.26 and its 200-day simple moving average is $6.08.

Hedge Funds Weigh In On Evolus

Several large investors have recently modified their holdings of the stock. Larson Financial Group LLC raised its holdings in Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock valued at $33,000 after acquiring an additional 2,837 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Evolus during the fourth quarter worth $34,000. Wexford Capital LP bought a new stake in shares of Evolus in the third quarter valued at about $37,000. California State Teachers Retirement System grew its stake in shares of Evolus by 79.9% in the second quarter. California State Teachers Retirement System now owns 5,455 shares of the company's stock valued at $38,000 after acquiring an additional 2,423 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in Evolus during the second quarter worth about $40,000. 90.69% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

EOLS has been the topic of a number of recent research reports. BTIG Research reiterated a "buy" rating and issued a $13.00 price objective on shares of Evolus in a report on Wednesday, June 17th. HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of Evolus in a report on Tuesday, August 25th. Wall Street Zen raised shares of Evolus from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, June 15th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $14.50.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source